Leaders of 3 health technology assessment organizations convene working group and steering committee to critically and independently research new health economic methods
The USA-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (…
The 2025 call for nominations to join expert and advisory committees at Canada’s Drug Agency will be open from March 3 to March 31, 2025.
These committees play a critical role in our efforts to power evidence-informed drug and health technology decisions and improve health outcomes for…
Canada’s Drug Agency has officially opened its call for nominations for the position of Chair of its Board of Directors. This is a unique opportunity to help shape how evidence is used to power decisions about drugs and health technologies and improve the quality, value, and sustainability of…
Recommendations will help organizations that appraise new drugs establish whether their use will result in longer-term benefits for patients
Four health technology assessment agencies, including Canada’s Drug Agency, have published new guidance on the use of surrogate endpoints in cost-…
Canada’s Drug Agency is seeking to expand the group of scientists who contribute their expertise to our organization and help us power evidence-informed health technology decisions.
Within our organization, there is a need for timely access to skills that can supplement our existing capacity and…
Consultation status: ClosedConsultation period: January 6 to February 6, 2025
Canada’s Drug Agency is outlining additional plans to modernize the drug reimbursement review process and is seeking feedback on our proposed approaches.
The consultation document, Proposed Improvements to the Drug…
Canada's Drug Agency (CDA-AMC) and the Canadian Institute for Health Information (CIHI) have signed a 3-year agreement that will leverage the strengths of both organizations to build a stronger drug data and analytics foundation across Canada. This work will aim to advance CIHI’s Pharmaceutical…
Canada’s Drug Agency has received a letter from The Honourable Mark Holland that outlines our time-limited work related to An Act respecting pharmacare, which received royal assent on October 10, 2024.
We have begun to undertake the work outlined in the legislation and the letter, building on our…
Canada’s Drug Agency is proud to welcome Maureen Smith as the first-ever Patient Member on our Board of Directors. Maureen is a respected leader in the field of patient engagement, and she brings a unique perspective to our table, grounded in lived and living experience.
For the past 25…
A new coalition, announced today, unites 11 organizations that are working collectively to improve the appropriate prescribing and use of medications in Canada.
Initially formed in 2023, the Appropriate Use Coalition is a grassroots group comprised of health care organizations and public…
Current consultation status: ClosedConsultation period: November 28 to January 28, 2025
Canada’s Drug Agency is launching a consultation on our first-ever methods guide. The development of the guide and our open consultation are both part of our ambition to increase the transparency of our…
Canada’s Drug Agency, with support from our health system partners including ICES and Health Data Research Network Canada (HDRN), has published a new roadmap that will help those who manage patient and disease registries in Canada navigate the process of linking data records to help answer relevant…